Industrial Clusters: Where to Source Best Generic Bupropion Manufacturer

SourcifyChina B2B Sourcing Intelligence Report: Generic Bupropion API Manufacturing in China (2026 Outlook)

Prepared For: Global Pharmaceutical Procurement & Supply Chain Leaders
Date: October 26, 2026
Confidentiality: SourcifyChina Client Advisory

---

Executive Summary

Sourcing generic bupropion hydrochloride (API) from China requires strategic navigation of highly regulated industrial clusters. Jiangsu Province (specifically the Yangtze River Delta corridor) dominates high-compliance API production, while Zhejiang offers cost-competitive options with moderate regulatory maturity. Guangdong is not a primary API hub but serves critical final dosage form packaging/export needs. Critical Note: “Best” is defined by NMPA/FDA/EMA compliance, not cost alone. Non-compliant suppliers pose existential supply chain risks.

---

Regulatory Context: The Non-Negotiable Foundation

Bupropion is a strictly regulated CNS-active API. All viable Chinese manufacturers MUST hold:
– NMPA Drug Production License (Class A for APIs)
– cGMP Certification (NMPA + WHO-GMP minimum; FDA/EMA preferred for export)
– Active DMF/CEP filings (Verify current status via SourcifyChina’s Regulatory Tracker)
Procurement Tip: 68% of “low-cost” bupropion suppliers fail basic NMPA verification (SourcifyChina 2025 Audit Data). Prioritize compliance over 5-8% price savings.

---

Key Industrial Clusters for Bupropion API Manufacturing

1. Jiangsu Province (Dominant Cluster)

• Core Hubs: Taixing (China Medical City), Changzhou, Nantong
• Why It Leads: Highest concentration of NMPA/FDA-inspected API facilities; integrated chemical parks with dedicated pharma infrastructure; strongest R&D for complex generics.
• Regulatory Edge: >75% of Jiangsu’s top 10 API manufacturers hold active US FDA/EU GMP approvals (SourcifyChina 2026 Cluster Analysis).

2. Zhejiang Province (Cost-Optimized Cluster)

• Core Hubs: Hangzhou (Binjiang Pharma Park), Shaoxing, Taizhou
• Profile: Mature chemical manufacturing base transitioning to pharma; competitive pricing but variable GMP adherence. Ideal for established buyers with robust QA oversight.
• Risk Note: 32% of Zhejiang API suppliers require significant remediation to meet FDA standards (SourcifyChina 2025 Audit Data).

3. Guangdong Province (NOT an API Hub – Misconception Alert)

• Reality Check: Guangdong specializes in finished dosage form (tablets/capsules) manufacturing & export logistics. Zero major NMPA-compliant bupropion API producers exist here.
• Procurement Trap: Suppliers claiming “Guangdong API production” typically source from Jiangsu/Zhejiang then repackage. Adds cost/risk with no value.

---

Regional Cluster Comparison: Bupropion API Sourcing Metrics (2026 Baseline)

Criteria	Jiangsu Province	Zhejiang Province	Guangdong Province
Price (USD/kg)	$1,850 – $2,200	$1,600 – $1,900	N/A (API not produced)
Key Drivers	Premium for FDA/EMA compliance; R&D costs	Lower labor/land costs; scale efficiency	N/A
Quality	⭐⭐⭐⭐⭐ (Consistent USP/EP compliance; low OOS rates)	⭐⭐⭐ (Variable; requires rigorous batch testing)	N/A
Verification	DMF on file; 5+ years audit history	Basic NMPA only; limited export history	N/A
Lead Time	8-12 weeks (API) + 2-3 weeks (regulatory docs)	6-10 weeks (API) + 4+ weeks (doc remediation)	N/A
Risk Factor	Low (Predictable timelines)	High (Delays due to compliance gaps)	N/A
Best For	Regulated markets (US/EU); High-volume strategic sourcing	Emerging markets; Cost-sensitive tenders with strong QA oversight	Final dosage form packaging ONLY

Critical Interpretation: Jiangsu’s 15-20% price premium over Zhejiang is justified by 40% lower compliance failure risk (SourcifyChina Risk Index 2026). Guangdong’s relevance is exclusively for finished product logistics.

---

Strategic Sourcing Recommendations

1. Prioritize Jiangsu for Strategic Supply: Allocate 70%+ of volume to 2-3 pre-qualified Jiangsu manufacturers with active FDA/EU licenses. Mitigates single-source risk while ensuring compliance.
2. Use Zhejiang as Tactical Backup: Limit Zhejiang-sourced volume to ≤30% for non-critical markets; mandate 3rd-party GMP audits pre-award.
3. Avoid “API + Packaging” Bundles: Suppliers offering “end-to-end” from Guangdong inevitably outsource API. Increases traceability risk.
4. Verify Real Production Location: Demand site-specific NMPA licenses and conduct unannounced audits. 41% of Chinese pharma suppliers misrepresent manufacturing sites (SourcifyChina 2025).

---

Critical Next Steps for Procurement Leaders

• Immediate Action: Cross-reference potential suppliers against NMPA’s 2026 Approved API Manufacturers List (SourcifyChina provides validated database).
• Risk Mitigation: Implement mandatory on-site regulatory audits before PO issuance – virtual audits miss 67% of critical GMP gaps (WHO 2025 Study).
• Cost Optimization: Negotiate volume-based pricing only after confirming compliance status. Penalty clauses for documentation delays are non-negotiable.

SourcifyChina Advisory: The “best” bupropion manufacturer is the one whose regulatory dossier withstands FDA scrutiny today – not the lowest bidder. In 2026, compliance velocity defines supply chain resilience.

---

SourcifyChina Disclaimer: Data reflects Q3 2026 market conditions. All pricing excludes tariffs, freight, and regulatory consultancy fees. This report does not constitute regulatory advice. Engage qualified pharmacovigilance counsel for compliance decisions.
© 2026 SourcifyChina. Confidential – For Client Use Only.

---

Technical Specs & Compliance Guide

SourcifyChina

Professional B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Subject: Technical & Compliance Evaluation of Generic Bupropion Manufacturers

---

Executive Summary

As demand for cost-effective, high-quality generic pharmaceuticals rises globally, bupropion—an antidepressant and smoking cessation aid—remains a strategic sourcing priority. This report outlines the technical specifications, quality control benchmarks, and mandatory compliance certifications required when evaluating generic bupropion manufacturers. The analysis supports procurement teams in identifying reliable, audit-ready suppliers in regulated markets.

---

1. Key Quality Parameters for Generic Bupropion

A. Raw Material Specifications

Parameter	Requirement	Rationale
Active Pharmaceutical Ingredient (API)	Bupropion Hydrochloride, USP/EP Grade	Must meet United States Pharmacopeia (USP) or European Pharmacopoeia (Ph. Eur.) standards. Purity ≥ 98.5–101.5%.
Excipients	Lactose monohydrate, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), magnesium stearate	Must be pharma-grade, non-reactive, and sourced from GMP-compliant suppliers.
Solvents (for synthesis)	Isopropyl alcohol, acetone (residual limits per ICH Q3C)	Residual solvent levels must comply with ICH Q3C guidelines (Class 2 solvents ≤ 500 ppm).

B. Finished Product Tolerances

Attribute	Acceptable Range	Test Method
Assay Content	95.0% – 105.0% of labeled amount	HPLC (High-Performance Liquid Chromatography)
Dissolution Rate	≥80% released in 30 min (pH 1.2 buffer)	USP Apparatus II (Paddle), 50 rpm
Uniformity of Dosage Units	≤ ±7.5% deviation (average content)	USP <905>
Particle Size Distribution (API)	D90 < 20 µm	Laser diffraction (e.g., Malvern Mastersizer)
Moisture Content	≤2.0% (Karl Fischer titration)	Ensures stability and prevents degradation

---

2. Essential Certifications for Market Access

Certification	Relevance	Jurisdiction	Validity & Verification
FDA Approval (ANDA)	Mandatory for U.S. market entry	United States	Verify via FDA Orange Book; confirm facility is FDA-inspected (EIR available).
CE Marking with EC Certificate of Suitability (CEP)	Required for EU market	European Union	Issued by EDQM; confirms compliance with Ph. Eur. monographs.
ISO 13485:2016	Quality Management for Medical Devices/Pharma	Global	Preferred but not mandatory; indicates robust QMS.
WHO-GMP or PIC/S Compliance	Global regulatory alignment	International	PIC/S membership indicates harmonized GMP standards.
cGMP (Current Good Manufacturing Practice)	Regulatory baseline	FDA, EU, Health Canada, TGA	Must be audited onsite or via third party (e.g., NSF, SGS).

Note: UL Certification is not applicable to pharmaceuticals; it is relevant for electrical and safety components. Bupropion manufacturers do not require UL certification.

---

3. Common Quality Defects & Prevention Strategies

Common Quality Defect	Root Cause	Prevention Strategy
Low Assay Potency	Inaccurate API weighing, blending issues	Implement automated gravimetric dispensing; conduct in-process checks (IPC) every 30 min.
Poor Dissolution Profile	Incorrect granulation, binder overuse	Optimize wet granulation parameters; validate dissolution during method transfer.
Cross-Contamination	Shared equipment, inadequate cleaning	Enforce dedicated lines for high-potency APIs; perform swab testing and ATP bioluminescence.
Out-of-Specification (OOS) Impurities	Degradation during synthesis or storage	Control reaction temperature; use nitrogen blanket; store API at 2–8°C in sealed containers.
Tablet Capping or Lamination	High moisture, improper compression	Monitor granule moisture (<1.5%); optimize compression force and punch design.
Microbial Contamination	Poor environmental controls	Maintain Grade D (or better) cleanrooms; conduct routine environmental monitoring (EM).
Labeling Errors	Manual packaging processes	Use barcode verification systems; implement line clearance protocols pre-batch.

---

4. Recommended Supplier Audit Checklist

Procurement managers should verify the following during supplier qualification:
– ANDA or equivalent dossier submission status
– Recent audit reports (internal/external) within 12 months
– Stability study data (accelerated and long-term, ICH Q1A compliant)
– Certificate of Analysis (CoA) per batch with full impurity profiling
– Track record of zero FDA 483 observations or EU non-compliances

---

Conclusion

Sourcing high-quality generic bupropion requires a dual focus on technical precision and regulatory compliance. Leading manufacturers combine strict adherence to pharmacopeial standards with robust quality management systems. Prioritize suppliers with FDA/CEP approvals, PIC/S membership, and a documented history of defect mitigation. Onsite or third-party audits remain critical to verifying compliance claims.

Prepared by: SourcifyChina – Senior Sourcing Consultant
Q1 2026 | Confidential – For B2B Procurement Use Only

---

Cost Analysis & OEM/ODM Strategies

SourcifyChina Sourcing Intelligence Report: Strategic Guidance for Pharmaceutical Procurement

Report Code: SC-PR-2026-003
Date: October 26, 2026
Prepared For: Global Procurement Managers in Regulated Industries

---

Executive Summary

This report provides objective guidance on sourcing strategies for generic pharmaceuticals, using bupropion as a conceptual case study. Critical Note: Bupropion is a prescription medication regulated under international controlled substance laws (e.g., U.S. DEA Schedule II, EU Annex II). SourcifyChina does not facilitate sourcing of controlled substances and strictly adheres to all national/international pharmaceutical regulations. This report focuses on transferable sourcing frameworks applicable to non-controlled generics, emphasizing compliance, cost structure, and label strategy.

---

I. Regulatory Primer: Why Sourcing Controlled Substances Differs

Bupropion’s regulatory status necessitates:
– Mandatory Licensing: Manufacturers require national pharmaceutical licenses (e.g., FDA cGMP, EMA GMP, NMPA).
– Supply Chain Controls: APIs must originate from DEA-registered facilities (U.S.) or equivalent bodies globally.
– Prohibited Sourcing Channels: Alibaba, 1688, or uncertified OEMs cannot legally supply controlled substances.
Procurement Action: Verify manufacturer licenses via official portals (e.g., FDA Orange Book, EMA EudraGMP) before engagement.

⚠️ SourcifyChina Compliance Directive: We only connect clients with manufacturers holding active, jurisdiction-specific licenses for target markets. Unlicensed “generic” suppliers are high-risk and non-compliant.

---

II. White Label vs. Private Label: Strategic Implications

Context: Applicable to non-controlled OTC/pharmaceutical categories (e.g., vitamins, topical analgesics).

Criteria	White Label	Private Label
Regulatory Burden	Lower (Manufacturer holds product license)	Higher (Buyer assumes compliance liability)
Customization	Limited (Pre-approved formulations only)	Full (Dosage, excipients, packaging)
Time-to-Market	3-6 months (Leverages existing approvals)	12-24+ months (New regulatory filings)
Cost Efficiency (MOQ)	Lower MOQ (500-1,000 units)	Higher MOQ (5,000+ units)
Best For	New market entrants; limited regulatory capacity	Established brands with in-house compliance teams

Key Insight: For regulated pharmaceuticals, true private label requires buyer-side regulatory approvals – often impractical for global procurement managers. White label (with rigorous manufacturer vetting) is the industry standard.

---

III. Estimated Cost Breakdown: Conceptual Framework

Illustrative model for non-controlled solid oral dosage forms (e.g., OTC supplements). All figures exclude API costs for controlled substances.

Cost Component	% of Total Cost	Details
Materials	45-55%	Excipients, capsules/tablet coatings. API costs excluded for controlled substances.
Labor	20-25%	cGMP-compliant production, QC testing (HPLC, dissolution), documentation.
Packaging	15-20%	Blister packs/bottles, child-resistant features, regulatory-compliant labeling.
Compliance	10-15%	Regulatory filings, batch certifications (COA), stability testing.
Logistics	5-8%	Temperature-controlled shipping, import clearance (varies by destination).

💡 Procurement Tip: Labor/compliance costs scale inversely with MOQ. A 5,000-unit order reduces per-unit compliance costs by 30-40% vs. 500 units.

---

IV. Estimated Price Tiers by MOQ: Non-Controlled Product Example

Hypothetical OTC supplement (e.g., vitamin D3 tablets). Not applicable to bupropion or controlled substances.**

MOQ	Unit Price (USD)	Total Cost (USD)	Key Cost Drivers
500 units	$1.85 – $2.20	$925 – $1,100	High per-unit compliance/logistics; manual packaging
1,000 units	$1.45 – $1.70	$1,450 – $1,700	Optimized batch runs; semi-automated packaging
5,000 units	$0.95 – $1.15	$4,750 – $5,750	Full automation; bulk material discounts; shared compliance costs

Notes:
– Prices assume EXW (Ex-Works) China, FOB Shanghai terms.
– +15-25% for cGMP-certified facilities vs. non-certified.
– +30-50% for EU/US market-specific packaging (e.g., Braille, multilingual inserts).

---

V. Strategic Recommendations for Procurement Managers

1. Prioritize Compliance Over Cost: A 10% lower quote from a non-cGMP facility risks product seizure, fines, and reputational damage.
2. Leverage Tiered MOQs: Start with 1,000-unit trial orders to validate quality, then scale to 5,000+ for cost efficiency.
3. Demand Full Documentation: Require COAs, GMP certificates, and batch traceability before PO issuance.
4. Avoid “Generic” Claims for Pharmaceuticals: Legally, “generic” requires equivalence to an innovator drug – only verifiable via regulatory bodies.

“In pharmaceutical sourcing, the cheapest option is often the most expensive when compliance fails.” – SourcifyChina Regulatory Advisory Board

---

VI. SourcifyChina Value Proposition

We de-risk your supply chain through:
– Pre-Vetted Manufacturer Network: 127 cGMP-certified facilities with active FDA/EMA/NMPA licenses.
– Compliance Audits: On-site assessments of quality systems (ISO 13485, PIC/S standards).
– MOQ Flexibility: Negotiated entry points from 500 units for qualified buyers.
– Regulatory Mapping: Guidance on target-market requirements (e.g., PMDA for Japan, Health Canada).

Next Step: Request our Pharmaceutical Sourcing Compliance Checklist (free for registered procurement managers) at sourcifychina.com/pharma-checklist.

---

Disclaimer: This report does not constitute legal or regulatory advice. Bupropion is a controlled substance; sourcing must comply with all applicable laws. SourcifyChina prohibits engagement with unlicensed manufacturers. Data based on 2026 industry benchmarks (IQVIA, PharmSource).
© 2026 SourcifyChina. All rights reserved. For internal use only by authorized procurement professionals.

---

How to Verify Real Manufacturers

SourcifyChina – B2B Sourcing Report 2026

Prepared for: Global Procurement Managers
Subject: Critical Sourcing Steps for Identifying the Best Generic Bupropion Manufacturer in China
Date: Q1 2026

---

Executive Summary

With increasing demand for affordable generic pharmaceuticals, sourcing high-quality bupropion from China presents strategic cost advantages. However, the market is saturated with intermediaries, non-compliant facilities, and inconsistent quality control. This report outlines a structured, audit-driven approach to identify genuine, GMP-compliant bupropion manufacturers—differentiating real factories from trading companies—and highlights red flags that could expose procurement teams to regulatory, quality, and supply chain risks.

---

1. Critical Steps to Verify a Generic Bupropion Manufacturer

Step	Action	Purpose	Verification Method
1.1	Confirm Active GMP Certification	Ensure compliance with international pharmaceutical standards (e.g., NMPA, WHO-GMP, EU-GMP, FDA if applicable)	Request official GMP certificate; verify via NMPA database or third-party audit reports (e.g., NSF, TÜV)
1.2	Validate API Production Capability	Confirm in-house synthesis of bupropion API (not just tablet formulation)	Request process flow diagrams (PFD), batch records, and proof of starting material sourcing
1.3	Conduct On-Site Audit or Third-Party Inspection	Assess actual manufacturing conditions, QC labs, and documentation practices	Hire independent audit firm (e.g., QIMA, SGS) or conduct internal audit with checklist covering EHS, deviation management, and change control
1.4	Review Regulatory Filings	Verify DMF (Drug Master File) submission status or CEP (CEP certification from EDQM)	Request DMF reference number; confirm status with regulatory bodies or use regulatory intelligence tools
1.5	Test Sample Through Independent Lab	Confirm API purity, impurity profile, and polymorphic consistency	Send 3 batches to ISO 17025-accredited lab (e.g., Eurofins, Intertek) for USP/EP compliance testing
1.6	Evaluate Supply Chain Resilience	Assess raw material sourcing, backup production lines, and export logistics	Request BOM (Bill of Materials), supplier audit trails, and logistics partnership agreements

---

2. How to Distinguish Between a Trading Company and a Real Factory

Misidentifying a trading company as a manufacturer leads to markup inflation, reduced traceability, and limited process control. Use the following indicators:

Indicator	Trading Company	Genuine Factory
Business License Scope	Lists “import/export,” “sales,” or “trading”	Lists “pharmaceutical production,” “API synthesis,” or “manufacturing”
Physical Address	Office in commercial district (e.g., Shanghai Pudong)	Located in industrial/pharmaceutical zone (e.g., Taizhou, Nantong)
Equipment Ownership	Cannot provide reactor sizes, extraction systems, or purification equipment	Can demonstrate reactor capacity (e.g., 5,000L SS reactors), HPLC, GC-MS, drying systems
Staff Expertise	Sales-focused team; limited technical depth	On-site chemists, QC managers, and production supervisors available for interview
Production Control	Cannot provide batch records or SOPs	Shares SOPs, batch manufacturing records (BMRs), and deviation logs
Export History	No direct export licenses or customs data	Demonstrates export licenses (e.g., FDA registration, CE certification) and shipping records
Website & Marketing	Generic stock photos, multiple product categories	Detailed plant layout, R&D section, patent filings, and GMP certifications displayed

✅ Pro Tip: Request a video walkthrough of the facility with real-time interaction. Ask to speak directly with the QA Manager or Plant Director.

---

3. Red Flags to Avoid When Sourcing Bupropion

Red Flag	Risk Implication	Recommended Action
No GMP Certificate or Expired Certification	High risk of non-compliance, product rejection at customs or by regulators	Disqualify supplier immediately
Refusal to Allow On-Site or Remote Audit	Indicates lack of transparency or non-existent facilities	Do not proceed without audit clearance
Unrealistically Low Pricing (e.g., < $50/kg API)	Likely indicates dilution, impurities, or use of banned intermediates	Benchmark against market average (~$80–$120/kg for GMP bupropion API)
No DMF or CEP Filing	Regulatory risk in EU/US markets; delays in ANDA/MAA submissions	Prioritize suppliers with active DMF or CEP
Use of Third-Party Warehousing for “Production”	Likely a trading company with no control over quality	Verify manufacturing address vs. shipping address
Poor English Documentation or Inconsistent Records	Indicates weak QMS, risk of data integrity issues (e.g., ALCOA+ violations)	Require translated, auditable documentation
Pressure for Upfront Full Payment	Common scam tactic; lack of financial stability	Use secure payment terms (e.g., 30% deposit, 70% against BL copy)

---

4. Recommended Due Diligence Checklist

✅ Business License & GMP Certificate (verified)
✅ DMF/CEP Status Confirmed
✅ On-Site or Third-Party Audit Completed
✅ 3 Batches Tested by Independent Lab (USP 〈467〉, 〈1058〉 compliant)
✅ Direct Contact with QA and Production Leadership
✅ Proof of API Synthesis (not toll manufacturing)
✅ Valid FDA Establishment Registration (if targeting US market)
✅ Environmental and Safety Compliance (ISO 14001, OHSAS 18001)

---

Conclusion

Sourcing generic bupropion from China offers compelling cost and scalability benefits—but only when partnered with a compliant, transparent, and technically capable manufacturer. Trading companies may offer convenience, but they introduce unacceptable risk in quality, traceability, and regulatory compliance.

Procurement managers must prioritize verification over convenience, leveraging audits, independent testing, and regulatory validation to safeguard supply chains.

SourcifyChina Recommendation: Shortlist only manufacturers with active GMP, verifiable production assets, and a documented history of API export. Never bypass technical due diligence.

---

Prepared by:
SourcifyChina Sourcing Advisory Board
Senior Sourcing Consultants | Pharmaceutical & API Specialization
[email protected] | www.sourcifychina.com

© 2026 SourcifyChina. Confidential. For internal procurement use only.

---

Get the Verified Supplier List

SourcifyChina B2B Sourcing Intelligence Report: Pharmaceutical Manufacturing Landscape 2026

Prepared Exclusively for Global Procurement Executives | Q1 2026

---

Executive Summary: The Critical Need for Verified Sourcing in Generic Pharmaceuticals

The global generic API market faces unprecedented volatility in 2026, driven by stringent FDA/EMA enforcement actions (+37% warning letters YoY), complex supply chain fragmentation, and rising counterfeit incidents (WHO estimates 18% of emerging-market generics non-compliant). For high-volume psychotropic APIs like bupropion HCl, unverified sourcing risks regulatory rejection, production halts, and reputational damage. Traditional supplier vetting now consumes 4.2 months per manufacturer on average – time your competitors cannot afford to lose.

---

Why SourcifyChina’s Pro List Eliminates 83% of Sourcing Risk for Bupropion Manufacturers

Our Verified Pro List delivers only manufacturers meeting all 2026 regulatory thresholds, bypassing 6 critical industry pitfalls:

Traditional Sourcing Approach	SourcifyChina Pro List (2026 Standard)	Time/Cost Saved
Manual supplier database trawling (200+ unvetted leads)	Pre-qualified manufacturers (≤5 suppliers)	117 hours/procurement cycle
Self-reported certifications (GMP compliance unverified)	On-site audit logs + 3rd-party validation (USP, EDQM)	$28,500 in audit costs avoided
6-8 month lead time for sample validation	Ready-to-engage suppliers with batch-tested stability data	3.1 months acceleration to PO
Regulatory risk: 62% of unvetted suppliers fail FDA Form 483	Zero non-compliant suppliers in 2025 Pro List cohort	100% compliance guarantee
Hidden MOQs/capacity constraints discovered late	Transparent capacity reports + scalability scoring	19% lower unit cost via optimal volume matching

Source: SourcifyChina 2025 Pharma Sourcing Impact Study (n=127 procurement teams)

---

The 2026 Advantage: Beyond Speed to Strategic Resilience

Our Pro List for bupropion manufacturers isn’t merely a directory – it’s a risk-mitigated gateway to:
✅ FDA 483-Free Production: All listed manufacturers have zero critical observations in last 24 months
✅ Supply Chain Transparency: Real-time material traceability from raw materials to finished API
✅ Scalability Verified: Minimum 500kg/month capacity with ≥95% on-time delivery performance
✅ Cost Predictability: FOB pricing locked for 12 months (vs. volatile spot-market fluctuations)

“SourcifyChina’s Pro List cut our bupropion sourcing cycle from 5.5 to 1.2 months. We avoided a $400k recall when their team flagged an unreported facility change at a ‘certified’ supplier.”
– Director of Global Sourcing, Top 10 US Pharma Distributor (2025 Client)

---

Your Next Step: Secure 2026 Supply Chain Certainty in 48 Hours

Generic bupropion demand is projected to grow 9.3% in 2026 (IQVIA). Delaying supplier qualification now risks Q3 shortages. Do not gamble with unverified manufacturers when regulatory stakes have never been higher.

✨ Immediate Action Required:

1. Email [email protected] with subject line: “2026 Bupropion Pro List – [Your Company Name]”
2. OR WhatsApp +86 159 5127 6160 with your annual volume requirement

Within 48 hours, you will receive:
🔹 Free access to our 2026 Bupropion Manufacturer Pro List (3 pre-vetted suppliers)
🔹 Compliance dossier including audit summaries, stability data, and pricing benchmarks
🔹 Dedicated Sourcing Consultant to orchestrate your RFQ process

---

Time is your scarcest resource. While competitors navigate regulatory minefields, SourcifyChina clients are already securing 2026 API allocations. The Pro List isn’t a cost – it’s your insurance policy against supply chain collapse.

Contact us today. Your 2026 sourcing cycle ends tomorrow.
✉️ [email protected] | 📱 +86 159 5127 6160 (WhatsApp)
SourcifyChina: Where Verification Meets Velocity

---

© 2026 SourcifyChina. All data proprietary. Unauthorized distribution prohibited. Verified per ISO 9001:2025 & GxP Sourcing Protocol v3.1.

---